If you see women between the ages of 40 and 60, you are already seeing menopause. The question is not whether it is in your waiting room. It is whether it is being recognized.
This article sets out why that recognition matters clinically, why the gap exists, and what closing it actually asks of a practice.
In Summary:
| More than 50 million women in the United States are in the menopause transition, and fewer than 4,500 clinicians hold menopause certification. |
| Your midlife patients are already presenting with menopausal symptoms. Most are being assessed and treated for something else. |
| The barrier is rarely interest or aptitude. It is that menopause was largely absent from clinical training for two decades. |
| Competence here is learnable, and it does not require becoming a menopause specialist. |
The numbers behind the gap
More than 50 million women in the United States are currently in the menopause transition. Fewer than 4,500 clinicians nationally hold certification as menopause practitioners. Those figures, published in May 2026, describe a mismatch that no amount of referral can absorb.
The consequence is not that women go without care. It is that they receive care from clinicians who were never taught this material, in appointments where menopause is not on the agenda.
Why the training gap exists
This is not a failure of individual clinicians. It is the downstream effect of a specific historical event.
After the Women’s Health Initiative findings were published in the early 2000s, hormone therapy prescribing fell sharply. Prescribing was not the only thing that declined. Menopause education thinned, research funding narrowed, and an entire cohort of clinicians completed training with almost no exposure to the subject.
Surveys of residency programs have repeatedly found that most trainees finish feeling unprepared to manage menopause. Those trainees are now practicing physicians, and the material they were not taught has not become any less relevant.
What this looks like in a clinic that is not looking for it
Menopausal symptoms do not arrive labeled. They arrive as new anxiety, disrupted sleep, joint pain, palpitations, migraines, dry eyes, worsening eczema, recurrent urinary tract infections, and difficulty concentrating.
Each of those is a reasonable presenting complaint in its own right, and each has a plausible non-hormonal explanation. So the anxiety is treated as anxiety, the joint pain is referred to rheumatology, the palpitations generate a cardiology workup, and the pattern connecting them is never assembled.
A recent mixed-methods survey of United States women aged 35 and over found that more than a third were unsure whether they had entered perimenopause at all. If the patient does not know, and the clinician is not asking, the conversation does not happen.
The clinical cost is measurable in years. Women commonly describe moving between four or five clinicians before anyone names the transition.
What is at stake beyond symptom relief
Symptom control matters, and it is not the whole argument.
Bone density declines fastest in the early postmenopausal years. Cardiovascular risk rises across the transition, and cardiovascular disease is the leading cause of death in postmenopausal women. Genitourinary symptoms progress rather than resolve, which means untreated cases become harder cases.
Midlife is therefore a window where relatively ordinary clinical actions, screening, risk assessment, and treating what is treatable, have long consequences. Missing the window does not produce an acute event. It produces a worse baseline a decade later.
What offering menopause care does not require
Saliva and hair cortisol tests sold direct to consumers give you a number. A number is not a diagnosis.
Cortisol varies with the time of day, with how you slept, with recent exercise, with illness, with alcohol, and with a range of medications including inhaled and topical steroids. Test on two different mornings and you can get two different answers, both of them normal.
There is also no established reference range for cortisol imbalance, because it is not a recognised clinical condition. So when a consumer report flags your result as outside the range, it is measuring you against a threshold that does not correspond to any diagnosis.
The tests used clinically are different. Each is chosen to answer a specific question, and what the result means depends on your symptoms and history rather than on the number by itself.
Where the commercial and clinical arguments meet
Facial puffiness has many causes, including salt intake, alcohol, poor sleep, allergy, thyroid disease, kidney disease Midlife women are among the most engaged patients in any practice. They attend, they follow through, and they are actively looking for a clinician who takes them seriously, because most of them have already met one who did not.
For practices that already serve this demographic, aesthetics in particular, the overlap is close to total. The patient in front of you for a cosmetic consultation is frequently the same patient not sleeping, not recognizing herself, and not being asked about either.
We would put the clinical case first and the business case second, in that order. But it is worth saying plainly that they point the same way.
Where to start
Start with the foundations rather than with protocols. Understanding what drives symptoms across the transition is what makes everything downstream, including treatment decisions, defensible.
EncorVita Academy exists for exactly this purpose: structured, accredited education for clinicians adding midlife women’s health to an existing practice, taught by clinicians who do this work. You can review the programs we have available within the academy.
No. Menopausal patients present across primary care, family medicine, internal medicine, endocrinology, dermatology, and aesthetic and specialty practices. What is required is the clinical framework, not a particular specialty.
Any practice seeing women aged roughly 40 to 60 is already seeing patients in the transition. The median age of perimenopause onset is around 45, with a median duration of four to eight years.
Referral is appropriate for complex cases. With fewer than 4,500 certified providers nationally, referral cannot be the primary answer for more than 50 million women.
Recognition, assessment, exclusion of mimicking conditions and clear explanation are valuable on their own. Prescribing decisions can follow later, or be referred, without leaving the patient with nothing.
You often do not, initially. Thyroid disease, anemia, depression and sleep apnea overlap substantially with the menopause symptom list and are all treatable. A hormonal explanation should open an assessment rather than close it.
The Menopause Society maintains a directory of certified practitioners at menopause.org. It is a reasonable starting point, though availability varies considerably by region.
